Insmed Incorporated
Insmed Incorporated (INSM) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · INSM · as of Jun 8, 2026
Key Statistics
Explore Insmed Incorporated Data
insm stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 35 · Buy rate: 94.3%
The INSM analyst consensus is Buy, based on ratings from 35 Wall Street analysts over the past 3 months. The average 12-month price target is $210.18, representing +123.07% upside from the current price of $94.22.
Competitors & Peers
insm competitorsINSM
A
ALC
CAH
GEHC
HLNStock Performance
Full HistoryAbout Insmed Incorporated
Insmed Incorporated a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium aviu…
what is insmed incorporated · insm stock overview · insmed incorporated company profile · who is insmed incorporated ceo · insm NASDAQ · insmed incorporated headquarters · insmed incorporated business segments
About Stock Overview & Key Data
Insmed Incorporated (INSM) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 1, 2000. As of the latest trading session, INSM stock price is $94.22, with a market capitalization of $20.4B. The stock has returned +33.31% over the past 12 months and -45.86% year-to-date.
According to 35 Wall Street analysts, the consensus rating for Insmed Incorporated stock is Buy, with an average 12-month price target of $210.18. In fiscal year 2025, Insmed Incorporated reported revenue of $606.4M and net income of -$1.3B. For detailed data — including Insmed Incorporated revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Insmed Incorporated (INSM) stock price is $94.22. The stock is traded on NASDAQ under the ticker symbol INSM. The 52-week range is $70.57 – $212.75.